CTX-M-14 β-lactamase-producing Citrobacter freundii isolated in Venezuela
© Millán et al; licensee BioMed Central Ltd. 2011
Received: 27 April 2011
Accepted: 31 May 2011
Published: 31 May 2011
A clinical isolate of C. freundii with reduced susceptibility to extended-spectrum β-lactams from a woman with cystocele associated with recurrent urinary tract infection was analyzed. Susceptibility tests, double disk synergy tests (DDST) and enzymatic activity by the agar iodometric method suggested the presence of ESBLs. Conjugation experiments revealed the presence of a large conjugative plasmid (pLM07/20) with an exclusive FrepB replicon type (IncF/FIB). PCR analysis and sequencing confirmed the presence of the blaCTX-M-14 gene in the pLM07/20 from C. freundii.LM07/10. Although this is the first report of CTX-M-14 in Venezuela, we alert the medical community that future increase of these β-lactamases in our city could be due to dissemination of plasmids into bacterial populations.
KeywordsCitrobacter freundii Extended-spectrum β-lactamases CTX-M-14, plasmid FrepB replicon
Extended-spectrum β-lactamases (ESBLs) create significant therapeutic problems by inactivating almost all β-lactams except cephamycins and carbapenems. Following the detection of the first ESBL, TEM and SHV-derived ESBLs evolved and disseminated globally up to the late 1990s. Since then, a new epidemiological situation lead to a predominant increase of CTX-M derived enzymes . Infections caused by ESBL-producing Enterobacteriaceae have mostly been described as hospital-acquired, associated with health care facilities , and, with increasing frequency, isolated from patients from both extended-care facilities and community-onset diseases [3, 4]. Citrobacter freundii is an opportunistic pathogen that can cause diarrhea, septicemia, meningitis, and respiratory and urinary tract infection, especially in high-risk groups . Multidrug resistance in Citrobacter spp. is a growing concern all over the world, and extended-spectrum cephalosporins are currently used to treat infections caused by these microorganisms. Numerous international molecular studies have also described the occurrence of various CTX-M types in species of Citrobacter, CTX-M-9 in the United Kingdom , CTX-M-30 in Canada , CTX-M-3 in Korea , CTX-M-2 in Japan , CTX-M-14 in China , and CTX-M-15 in India . However, the distribution of CTX-M producers among community-onset pathogens from South America, especially in Venezuela, remains scarcely known. In this report, we describe a clinical isolate of C. freundii with reduced susceptibility to extended-spectrum cephalosporins that produces a CTX-M-14 type β-lactamase, from a woman with cystocele and urinary infection.
In June 2010, a 47-year-old woman was assisted in private consulting with a history of grade II cystocele and recurrent urinary tract infection since December 2009. One cephalosporin-resistant strain of Citrobacter freundii LM07/10 was isolated from an urine sample. The strain was identified using conventional biochemical tests and confirmation was realized by API 20E system (bioMérieux, Marcy l'Etoile, France). The patient was treated according to the susceptibility test with i.v. meropenem. Also, a surgical treatment to repair the anterior vaginal wall prolapse was suggested.
Antimicrobial susceptibility testing was determined using the agar dilution method according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) . The following antimicrobials (Valmorca, Mérida, Venezuela) were tested: cefoxitin, cefotaxime, ceftazidime, ceftazidime plus clavulanic acid, aztreonam, imipenem, meropenem, ciprofloxacin, gentamicin, amikacin and tobramycin. The ESBL phenotype was detected by the double disk (Oxoid, Basingstoke, Hampshire, England) synergy test (DDST) according to CLSI  guidelines. The quality control strains used were Escherichia coli ATCC 25922 (negative control for ESBL) and Enterobacter cloacae UBA-G CTX-M-9 (positive control for ESBL). β-lactamase presence in crude extracts obtained by sonication was confirmed by an agar iodometric method  with minor modifications  using cefotaxime as substrate.
To determine whether the resistance was transferable, conjugation experiments using mixed broth cultures were performed with E. coli J53 (azideR) as recipient. Transconjugants were selected on Levine agar (Britania, Buenos Aires, Argentina) plates containing 75 μg/ml of azide and 2 μg/ml of cefotaxime. The presence of blaCTX-M genes in the transconjugants was confirmed by DDST and PCR. Plasmid DNA from transconjugants was extracted by the rapid alkaline lyses method  and then analyzed by electrophoresis on a 0.8% agarose gel and visualized by staining with ethidium bromide under UV light. Identification of plasmids by PCR-based replicon typing was carried out as described by Carattoli et al. .
Detection of antimicrobial resistance blaCTX-M and blaCTX-M-9 genes were performed by PCR amplification using the following primers sets : CTX-M-GF- 5'ATG TGC AGY ACC AGTA ARG TKA TGG C '3 and CTX-M-GR- 5' CCG CTG CCG GTY TTA TCV CCB AC '3 for blaCTX-M; CTX-M-9F- 5'AAC ACG GAT TGA CCG TCT TG '3 and CTX-M-9R- 5' TTA CAG CCC TTC GGC GAT '3 for blaCTX-M-9. The presence of the other β-lactamase genes was determined by previously described primers . DNA templates were prepared by suspending one or two fresh colonies in 200 μl of sterile distilled water and heating at 95°C for 10 min. Amplification was performed in a final volume of 25 μl containing 1 μM of each primer, 0.2 mM of dNTPs, 1.5 mM MgCl2 and 1 unit of Taq polymerase. PCR products were visualized by electrophoresis on 1% agarose gels, stained with ethidium bromide (50 μg/ml) and photographed with UVP Biodoc-It System. Amplification products were purified (Sigma PCR Cleanup kit) and their nucleotide sequencing was performed with the ABI Prism 377 genetic analyzer (Applied Biosystems, CA, USA). Nucleotide and amino acid sequence alignments were analyzed using the Basic Local Alignment Search Tool (BLAST) suite of programs (http://www.ncbi.nlm.nih.gov/BLAST.cgi).
Recurrent urinary tract infection (UTI) remains an important public health problem in women of all ages . We reported a case of a woman with grade II cystocele associated with recurrent UTI. This patient had more than three microbiologically documented episodes of symptomatic UTI during the last 6 months. Initially the patient was managed with empirical first line antibiotic therapy (amoxicillin or cephalexin) and later with extended-spectrum cephalosporins (ceftriaxone or cefotaxime). Recurrent infections are of particular concern because of the repeated morbidity and necessity for frequent administration of antibiotics with the possible adverse consequences of selection of antimicrobial-resistant strains.
Antibiotic susceptibility (MIC) of ESBL-producing Citrobacter freundii LM07/10 and Escherichia coli J53-07/20 transconjugants.
E. coli J53-07/20
E. coli J53
Further DNA templates of C. freundii LM07/10, E. coli J53-07/20 transconjugants and plasmid (pLM07/20) were screened by PCR assays for blaTEM, blaSHV and blaCTX-M genes. Primers specific to the blaCTX-M-9 group gave positive gene amplification (850 bp fragment). Sequence analysis of the amplification product revealed the presence of blaCTX-M-14.
ESBLs-producing Enterobacteriaceae were previously identified in the small number of studies of venezuelan hospital-derivated isolates [20–23]. Previous reports of genotypes of ESBL genes from Venezuela were sporadic and involved SHV-5 and CTX-M-2, being particularly common in Klebsiella pneumoniae of nosocomial origin [20–22]. Also, the distribution of different genotypes of ESBLs in hospital or community in Venezuela is poorly understood. This is the first report of a CTX-M-14 β-lactamase producing C. freundii in Venezuela associated with a large conjugative plasmid with an exclusive FrepB replicon type (IncF/FIB) isolated from a community patient. But previous studies indicated that others replicons of different incompatibility groups (IncI or IncK) can also be involved in the dissemination of CTX-M-14 [24, 25].
Recent studies suggest that infections due to ESBLs-producing organisms might be an emerging problem in outpatient settings in different countries [3, 26]. Few data regarding the molecular epidemiology of CTX-M type ESBLs-producing C. freundii isolated from patient with community-onset infections are available [17, 26]. According to the findings from this study, we may assume the hypothesis that microorganisms with antibiotic resistance mechanisms can be present in patients in the community and it is possible that healthy people could act as a reservoir of these ESBLs as a consequence of antibiotic use and abuse. Only through the recognition of factors associated with increasing resistance and the study of the molecular mechanisms involved, strategies can be traced and β-lactam resistance minimized.
In conclusion, this study supports the view that CTX-M-14 producing C. freundii is an emerging pathogen in community settings in Mérida, Venezuela, and that increased efforts in surveillance and study of risk factors associated with these bacteria are needed.
Patient's written informed consent was obtained for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
This study was carried out within the research activities of the Bacterialnet project, ALFA II Contract N° II-531-FC-FA-FCD-FI and partially supported by Consejo de Desarrollo Científico, Humanístico y Tecnológico (CDCHT-ULA) of University of The Andes, Mérida-Venezuela (grant CVI-ADG-FA-02-97).
- Pitout JDD: Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae. Changing epidemiology and drug treatment choices. Drugs. 2010, 70 (3): 313-333. 10.2165/11533040-000000000-00000View ArticlePubMed
- Falagas ME, Karageorgopoulos DE: Extended-spectrum β-lactamase-producing organisms. J Hosp Infect. 2009, 73: 345-354. 10.1016/j.jhin.2009.02.021View ArticlePubMed
- Rodríguez-Baño J, Pascual A: Clinical significance of extended-spectrum β-lactamases. Expert Rev Anti Infect Ther. 2008, 6 (5): 671-683. 10.1586/14787188.8.131.521View ArticlePubMed
- Rossi A. Galas M, Corso A, Radice M, Rivas M, Caffer M, Binztein N, Gutkind G: Unussual multiresistant Vibrio cholerae O1 var. El Tor in Argentina. Lancet. 1993, 342: 1172-1173.View ArticlePubMed
- Lavigne JP, Defez C, Bouziges N, Mahamat A, Sotto A: Clinical and molecular epidemiology of multidrug-resistant Citrobacter spp. infections in a French university hospital. Eur J Clin Microbiol Infect Dis. 2007, 26: 439-441. 10.1007/s10096-007-0315-3View ArticlePubMed
- Munday CJ, Whitehead GM, Todd NJ, Campbell M, Hawkey PM: Predominance and genetic diversity of community- and hospital acquired CTX-M extended-spectrum β-lactamases in York, UK. J Antimicrobial Chemother. 2004, 54: 628-633. 10.1093/jac/dkh397.View Article
- Abdalhamid B, Pitout JDD, Moland ES, Hanson ND: Community-onset disease caused by Citrobacter freundii producing a novel CTX-M β-lactamase, CTX-M-30, in Canada. Antimicrob Agents Chemother. 2004, 48: 4435-4437. 10.1128/AAC.48.11.4435-4437.2004View ArticlePubMedPubMed Central
- Kim J, Lim YM: Prevalence of derepressed AmpC mutants and extended-spectrum β-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12. J Clin Microbiol. 2005, 43: 2452-2455. 10.1128/JCM.43.5.2452-2455.2005View ArticlePubMedPubMed Central
- Muta T, Tsuruta N, Seki Y, Ota R, Suzuki S, Shibata N, Kato K, Eto T, Gondo H, Arakawa Y: A nosocomial outbreak due to novel CTX-M-2-producing strains of Citrobacter koseri in a hematological ward. Jpn J Infect Dis. 2006, 59: 69-71.PubMed
- Zhang R, Yang L, Cai JC, Zhou HW, Chen GX: High level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and porin expression. J Med Microbiol. 2008, 57: 332-337. 10.1099/jmm.0.47576-0View ArticlePubMed
- Shahid M: Citrobacter spp. simultaneously harboring blaCTX-M, blaTEM, blaSHV, blaampC, and insertion sequences IS26 and orf 513: an evolutionary phenomenon of recent concern for antibiotic resistance. J Clin Microbiol. 2010, 48: 1833-1838. 10.1128/JCM.01467-09View ArticlePubMedPubMed Central
- Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing, 21th informational supplement. CLSI Document M100-S20. Wayne, PA. 2011
- Labia R, Barthélémy M: Beta-lactamase enzymogram": an agar adaptation of the iodometric method. Ann Microbiol. 1979, 30B (3): 295-304.
- Rossi A, Lopardo H, Picandet AM, Mariño M, Galds M, Radice M, Gutkind G: Non-Typhoid Salmonella spp. resistant to cefotaxime. J Antimicrobial Chemother. 1995, 36 (4): 697-702. 10.1093/jac/36.4.697.View Article
- Birnboim HC, Doly J: A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acid Res. 1979, 7: 1513-1523. 10.1093/nar/7.6.1513View ArticlePubMedPubMed Central
- Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ: Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005, 63: 219-228. 10.1016/j.mimet.2005.03.018View ArticlePubMed
- Minarini LAR, Poirel L, Trevisani NAC, Darini ALC, Nordmann P: Predominance of CTX-M-type extended-spectrum β-lactamase genes among enterobacterial isolates from outpatients in Brazil. Diagn Microbiol Infect Dis. 2009, 65: 202-206. 10.1016/j.diagmicrobio.2009.05.021View ArticlePubMed
- Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, Rottensterich E, Stamm WE: Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis. 2000, 30: 152-156. 10.1086/313596View ArticlePubMed
- Carattoli A: Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother. 2009, 53: 2227-2238. 10.1128/AAC.01707-08View ArticlePubMedPubMed Central
- Araque M, Nieves B, Lauretti L, Rossolini GM: Molecular basis of extended-spectrum β-lactamase production in nosocomial isolates of Klebsiella pneumoniae from Mérida, Venezuela. Int J Antimicrob Agents. 2000, 15: 37-42. 10.1016/S0924-8579(99)00168-5View ArticlePubMed
- Araque M, Rivera I: Simultaneous presence of blaTEM and blaSHV genes on a large conjugative plasmid carried by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Am J Med Sci. 2004, 327: 118-122. 10.1097/00000441-200403000-00002View ArticlePubMed
- Guzmán M, Alonso G: Caracterización de β-lactamasas de espectro extendido (BLEE) en cepas nosocomiales de K. pneumoniae. Sucre-Venezuela. Inves Clin. 2009, 50: 419-431.
- Torres L, Gagliotta V, Torres O, Benitez M, Dominguez M, Pedroza R: β-lactamasa de espectro expandido en enterobacterias aisladas en centros de salud de Caracas. Rev Soc Venez Microbiol. 2006, 26: 80-88.
- Marcadé G, Deschamps C, Boyd A, Gautier V, Picard B, Branger C, Denamur E, Arlet G: Replicon typing of plasmids in Escherichia coli producing extended-spectrum β-lactamases. J Antimicrob Chemother. 2009, 63: 67-71.View ArticlePubMed
- Valverde A, Cantón R, Garcillán-Barcia MP, Novais A, Galán JC, Alvarado A, de la Cruz F, Baquero F, Coque TM: Spread of blaCTX-M-14 is driven mainly by IncK plasmids disseminated among Escherichia coli phylogroups A, B1, and D in Spain. Antimicrob Agents Chemother. 2009, 53: 5204-5212. 10.1128/AAC.01706-08View ArticlePubMedPubMed Central
- Pitout JDD, Gregson DB, Church DL, Elsayed S, Laupland KV: Community-wide outbreaks of clonally related CTX-M-14 β-lacatmase-producing Escherichia coli strains in the Calgary health region. J Clin Microb. 2005, 43: 2844-2849. 10.1128/JCM.43.6.2844-2849.2005.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.